It is well understood that driver gene fusions are typically found to be recurrent, such as BCR-ABL, ETV6-NTRK3, and TMPRSS2-ERG in prostate cancer [47], and consequently they are ideal targets for therapeutic intervention. This evidence concerns the gene TMPRSS2 and prostate carcinoma.